SHIELD-RSV: Next-Generation RSV Vaccine in Older Adults

A single-dose immunogenicity and safety study of an mRNA-based respiratory syncytial virus vaccine in adults aged 60 and older.

Key eligibility criteria

• Adults ≥ 60 years
• Generally good health
• No RSV vaccination in past 2 years
• No immunosuppressive therapy

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.